These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 25162961

  • 1. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
    Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, Day ES, Demeule B, Liu J, Shire SJ, Ferrara N, Yadav S.
    Mol Pharm; 2014 Oct 06; 11(10):3421-30. PubMed ID: 25162961
    [Abstract] [Full Text] [Related]

  • 2. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL, Lang GK, Lang GE.
    Exp Eye Res; 2014 May 06; 122():20-31. PubMed ID: 24631334
    [Abstract] [Full Text] [Related]

  • 3. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A, Grotelüschen S, Treumer F, Roider J, Hillenkamp J.
    Br J Ophthalmol; 2015 Jun 06; 99(6):864-9. PubMed ID: 25740806
    [Abstract] [Full Text] [Related]

  • 4. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
    MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N.
    Angiogenesis; 2016 Jul 06; 19(3):389-406. PubMed ID: 27234973
    [Abstract] [Full Text] [Related]

  • 5. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
    Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Spitzer MS, Aisenbrey S.
    Br J Ophthalmol; 2013 Jul 06; 97(7):917-23. PubMed ID: 23686000
    [Abstract] [Full Text] [Related]

  • 6. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
    Deissler HL, Deissler H, Lang GK, Lang GE.
    Exp Eye Res; 2013 Oct 06; 115():162-71. PubMed ID: 23891860
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF.
    Retina; 2012 Mar 06; 32(3):434-57. PubMed ID: 22374154
    [Abstract] [Full Text] [Related]

  • 8. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.
    Deissler HL, Lang GK, Lang GE.
    Graefes Arch Clin Exp Ophthalmol; 2015 Jun 06; 253(6):885-94. PubMed ID: 25663437
    [Abstract] [Full Text] [Related]

  • 9. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
    Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M.
    Exp Eye Res; 2007 Oct 06; 85(4):425-30. PubMed ID: 17714704
    [Abstract] [Full Text] [Related]

  • 10. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M.
    Am J Ophthalmol; 2014 Oct 06; 158(4):738-744.e1. PubMed ID: 24973606
    [Abstract] [Full Text] [Related]

  • 11. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM, Deobhakta A, Yoon D, Lee M, Slakter JS, Klancnik JM, Thompson D, Freund KB.
    Retina; 2014 Nov 06; 34(11):2161-6. PubMed ID: 25072648
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA.
    Br J Ophthalmol; 2015 Feb 06; 99(2):141-6. PubMed ID: 25271911
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal aflibercept for neovascular age-related macular degeneration.
    Xu D, Kaiser PK.
    Immunotherapy; 2013 Feb 06; 5(2):121-30. PubMed ID: 23413903
    [Abstract] [Full Text] [Related]

  • 14. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N, Terasaki H, Shirasawa M, Kawano H, Sonoda S, Yamaguchi M, Hashiguchi T, Hisatomi T, Ishibashi T, Sakamoto T.
    Retina; 2017 Jan 06; 37(1):179-190. PubMed ID: 28005721
    [Abstract] [Full Text] [Related]

  • 15. [Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins].
    Lang GE, Lang GK, Deissler HL.
    Klin Monbl Augenheilkd; 2015 Mar 06; 232(3):295-302. PubMed ID: 25393440
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A, Recber M, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct 06; 252(10):1593-8. PubMed ID: 25047874
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
    Deissler HL, Deissler H, Lang GE.
    Br J Ophthalmol; 2011 Aug 06; 95(8):1151-6. PubMed ID: 21273213
    [Abstract] [Full Text] [Related]

  • 18. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy.
    Kanda A, Noda K, Saito W, Ishida S.
    Sci Rep; 2015 Dec 09; 5():17946. PubMed ID: 26648523
    [Abstract] [Full Text] [Related]

  • 19. The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells.
    Arnott C, Punnia-Moorthy G, Tan J, Sadeghipour S, Bursill C, Patel S.
    PLoS One; 2016 Dec 09; 11(3):e0150688. PubMed ID: 26959822
    [Abstract] [Full Text] [Related]

  • 20. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G, Anfuso CD, Olivieri M, Lupo G, Caporarello N, Eandi CM, Drago F, Bucolo C, Salomone S.
    Biochem Pharmacol; 2015 Aug 01; 96(3):278-87. PubMed ID: 26056075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.